These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 542805)

  • 1. Transient acquired resistance to the coumarin anticoagulants phenprocoumon and acenocoumarol.
    de Wolff FA; ten Cate JW
    Scand J Haematol; 1979 Nov; 23(5):437-41. PubMed ID: 542805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Syncumar induced toxic liver damage].
    Göndöcs C; Szalay L; Baló-Banga JM; Fehér J
    Orv Hetil; 1990 Jul; 131(27):1477-9. PubMed ID: 2377369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.
    Gadisseur AP; van der Meer FJ; Adriaansen HJ; Fihn SD; Rosendaal FR
    Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenprocoumon and acenocoumarol treatment in paediatric patients.
    Spoor N; Smiers FJ; van der Meer FJ; Hutten BA; van Ommen CH
    Thromb Haemost; 2012 Dec; 108(6):1238-41. PubMed ID: 23014894
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants.
    Penning-van Beest FJ; Koerselman J; Herings RM
    J Thromb Haemost; 2008 Feb; 6(2):284-90. PubMed ID: 18031295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases.
    Neef M; Kerekes Z; Fischer HP; Sauerbruch T; Spengler U
    Digestion; 2003; 67(1-2):100-4. PubMed ID: 12743448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Teratogenic effect of coumarin derivatives].
    Weenink GH; van Dijk-Wierda CA; Meyboom RH; Koppe JG; Staalman CR; Treffers PE
    Ned Tijdschr Geneeskd; 1981 May; 125(18):702-6. PubMed ID: 7231584
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lead concentration in blood during treatment with coumarin derivatives].
    Fischer H; Wehran HI
    Z Arztl Fortbild (Jena); 1978 Mar; 72(5):211. PubMed ID: 418581
    [No Abstract]   [Full Text] [Related]  

  • 14. Understanding low INR in clinical practice.
    Hylek EM; Rose AJ
    Thromb Haemost; 2009 Mar; 101(3):417-8. PubMed ID: 19277399
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
    Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
    Wilms EB; Touw DJ; Conemans JM; Veldkamp R; Hermans M
    J Thromb Haemost; 2008 Jul; 6(7):1224-6. PubMed ID: 18419745
    [No Abstract]   [Full Text] [Related]  

  • 19. [Death of Sintrom?].
    Vogel J
    Rev Med Suisse; 2012 Jan; 8(325):164-5. PubMed ID: 22338498
    [No Abstract]   [Full Text] [Related]  

  • 20. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship.
    Thijssen HH; Hamulyák K; Willigers H
    Thromb Haemost; 1988 Aug; 60(1):35-8. PubMed ID: 3187945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.